Opinion|Videos|February 20, 2025
Strategies for Adverse Events Management with First-Line Amivantamab + Lazertinib and Osimertinib-Based Regimens in EGFR-mutated Metastatic NSCLC.
Author(s)Misako Nagasaka, MD, PhD
The panelist discusses how, Healthcare professionals manage distinct toxicities with ami+laz (IRRs, rash) and osi+chemotherapyctx (cytopenias, diarrhea, fatigue). SKIPPirr informs IRR mitigation in ami’s first infusion. Proactive AE strategies include premedication, dose adjustments, supportive care, and monitoring.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the toxicity differences you encounter when using i.e. combination ami+laz, chemotherapyosi+ctx?
- Please discuss your proactive AE management strategies.
- Ami/Laz: How does recent data from SKIPPirr inform your approach to managing IRRs in that first infusion of amivantamab? What proactive AE management strategies do you implement for dermatological toxicities like rash.
- chemotherapyOsi/ Ctx: What are proactive AE management strategies for cytopenias, diarrhea and fatigue?
Advertisement
Related to this article
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
3
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
4
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
5